Large Animal Neuroscience Lead
Subsense
Large Animal Neuroscience Lead
Subsense
Develops noninvasive nanotech BCI devices
Subsense is a deep-tech company developing the world’s first non-surgical, bidirectional brain-computer interface powered by plasmonic and magnetoelectric nanoparticles. Our mission is to unlock direct communication between the human brain and AI - starting with medical applications such as stroke recovery and moving toward cognitive enhancement for healthy users. Headquartered in Palo Alto, Subsense brings together leading scientists and engineers to redefine the future of human–machine interaction.
We're looking for a Large Animal Neuroscience Lead to lead the transition of our nanoparticle-based neurotechnology platform from rodents to large animals. This is a hands-on scientific leadership role: you'll run pig neuroscience experiments, manage CRO partnerships, and lead a 3–4-person team. Your initial focus will be rapid, rigorous, acute, non-GLP proof-of-concept studies that establish nanoparticle delivery, neural target engagement, and system performance. You'll work closely with nanoscience, hardware, software, data science, and R&D leadership to adapt research hardware, evaluate intranasal administration, and turn experimental results into clear development decisions.
You'd be joining a small team developing a non-surgical, bidirectional brain-computer interface powered by plasmonic and magnetoelectric nanoparticles. You’ll help translate early research into working technology, with the opportunity to influence both the platform and how we build it.
A few things that make this different:
If you’re drawn to hard problems, hands-on discovery, and the opportunity to turn research into working technology, we’d like to hear from you.
Subsense develops nanotechnology-based noninvasive brain-computer interfaces and medical devices aimed at treating neurodegenerative diseases. Its products are designed for daily, seamless use in healthcare, combining brain signal interfaces with nanotech to aid patients and clinicians. The company works with academic experts from ETH Zurich and Stanford to guide research and development, and plans to sell or license its BCI devices in Europe and the USA. Compared with competitors, Subsense emphasizes noninvasive, nano-scale interfaces and strong collaborations to translate research into market-ready medical devices. The overarching goal is to improve quality of life for individuals with neurodegenerative conditions by delivering practical, clinician-friendly BCI solutions.
Explore more opportunities at Subsense